Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE:DGX) subsidiary Haystack Oncology announced a research collaboration with Mass General Brigham to conduct two clinical trials studying Haystack MRD™, a ctDNA minimal residual disease test. The trials will investigate the test's effectiveness in guiding post-surgical treatment decisions for cutaneous squamous cell carcinoma (CSCC) and HPV-independent head and neck squamous cell carcinoma (HNSCC).

The studies will analyze patient samples at multiple timepoints to evaluate Haystack MRD's clinical utility. A recent NEJM study showed the test could identify clinical complete response at 1.4 months compared to over six months using imaging tests. According to a Harris Poll, 96% of oncologists believe MRD testing can detect cancer recurrence earlier than traditional methods.

Quest Diagnostics (NYSE: DGX) has completed its acquisition of select clinical testing assets from Spectra Laboratories, owned by Fresenius Medical Care. The deal positions Quest to provide dialysis-related clinical testing to independent dialysis clinics previously served by Spectra.

Under a separate laboratory services agreement, Quest will begin providing comprehensive dialysis-related laboratory services for Fresenius Medical Care's U.S. dialysis centers, serving approximately 200,000 patients annually. The service transition will start this month and is expected to complete by early 2026.

The strategic acquisition will leverage Quest's laboratory network to reduce transportation time and expedite results reporting. Quest plans to optimize capital returns by utilizing its facilities during lower-volume daytime hours.

Quest Diagnostics (NYSE: DGX) subsidiary Athena Diagnostics has launched a new laboratory test service for improved genetic testing of ataxia, a group of degenerative neurological disorders affecting movement and coordination. The test, developed in collaboration with PacBio (NASDAQ: PACB), utilizes PacBio's PureTarget sequencing method to identify long DNA repeat sequences that conventional testing might miss.

The new test will serve as a confirmatory tool following initial PCR screening, with testing conducted at Athena's Marlborough laboratory. A preprint study demonstrated the test's ability to identify specific gene patterns in Spinocerebellar ataxia type 10, potentially helping predict disease onset. Recent studies indicate ataxia affects 26 per 100,000 children, with genetic causes accounting for 10 per 100,000 cases.

Quest Diagnostics (NYSE:DGX) reported strong Q2 2025 financial results, with revenues reaching $2.76 billion, up 15.2% year-over-year. The company's reported diluted EPS increased 21.7% to $2.47, while adjusted diluted EPS grew 11.5% to $2.62.

Key performance metrics include a 16.3% increase in requisition volume, with organic requisition volume up 2.1%. Operating income rose 23.3% to $438 million, and cash from operations surged 67.1% to $858 million year-to-date.

Following these strong results, Quest has raised its full-year 2025 guidance, now expecting net revenues between $10.80-10.92 billion and adjusted diluted EPS of $9.63-9.83. The company attributes its performance to innovative clinical solutions, expanded enterprise accounts, and operational efficiency gains through automation and digital technologies.

Quest Diagnostics (NYSE: DGX) has announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging infectious disease prevalent in South and Central America and the Caribbean. The test, developed at Quest's San Juan Capistrano laboratory, will be available with a prescription by the end of July 2025.

The diagnostic solution employs PCR technology for early-stage detection, with serology testing planned for later in the quarter. This development follows Quest's CDC contracts awarded in September 2024 to support testing readiness for emerging infectious diseases. The initiative demonstrates Quest's role in preparing the U.S. healthcare system for potential public health threats.

[ "Development of first commercial diagnostic test for Oropouche virus in response to CDC contract", "Expansion of testing capabilities with both PCR and upcoming serology testing options", "Strategic positioning for potential public health threats through CDC contract funding" ]

Quest Diagnostics (NYSE: DGX) announced plans to offer the first FDA-cleared blood-based test for Alzheimer's disease, the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio. The test will be available for clinical and research use starting summer 2025.

The FDA-cleared test demonstrated impressive clinical results with a 92% positive predictive value and 97% negative predictive value in a study of 499 patients. It's designed for adults aged 50+ showing signs of cognitive decline in specialized care settings. Quest will provide the test through its network of approximately 8,000 patient access points, including 2,000 patient service centers across the U.S.

This addition complements Quest's existing AD-Detect™ portfolio of blood tests for Alzheimer's assessment, offering a less invasive and more convenient alternative to traditional amyloid PET imaging and spinal fluid testing methods.

Quest Diagnostics (NYSE: DGX) has released its 2024 Corporate Responsibility Report titled "Care Starts Here," highlighting the company's achievements across four strategic pillars: health access, employee and community engagement, governance and ethics, and environmental sustainability.

Key accomplishments in 2024 include: $13 million in corporate giving and Foundation grants, support for nearly 40 programs through the Quest Diagnostics Foundation, provision of one million donated or discounted test requisitions, and introduction of 50 new testing services. The company also spent $300 million with small U.S. businesses and welcomed Robert Carter, former FedEx CIO, to its board of directors.

Environmental initiatives included reducing electricity and single-use plastics usage, transitioning to electric and hybrid vehicles, and pursuing ISO 14001-2015 certification for additional facilities.

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has scheduled the release of its Q2 2025 financial results for July 22, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results. Participants can join via phone using specific dial-in numbers for U.S./Canada (888-455-0391) and international callers (773-756-0467) with passcode "7895081". The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until August 5, 2025, through the website or dedicated phone numbers. The company recommends reviewing their SEC periodic reports for risk factors and historical financial information.

Quest Diagnostics (NYSE: DGX) has announced a collaboration with MD Anderson Cancer Center to develop a novel Multi-cancer Stratification Test (MCaST) blood test. The test will assess elevated risk for multiple cancers including colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal and stomach cancers. Based on technology developed by Dr. Samir Hanash's team at MD Anderson, the test uses circulating protein biomarkers and was validated through extensive clinical research involving tens of thousands of individuals. Quest plans to commercialize the test in North America by 2026, positioning it as a supplement to conventional screening methods. The test aims to provide a more accessible, affordable alternative to current screening methods, addressing the concerning statistic that only 51% of U.S. adults undergo routine medical appointments or cancer screenings annually.